
iSearch v2.5: Summary of New Features

iSearch is NIH's next-generation portfolio analysis platform, providing comprehensive, easy-to-use access to a carefully curated, extensively linked data set of global grants, patents, publications, clinical trials, and approved drugs.

https://itools.od.nih.gov/dashboard/

Visualization tool – This tool uses text mining to create clusters of similar applications in any module of *iSearch*. It has now been updated to:

 Allow users to select various fields to text mine and create visualizations from chosen fields



Transfer – *iSearch* allows users to transfer results from one module to another, i.e. from grants to outputs such as publications or patents

 The record limit has been increased for interactive transfers (versus exporting) along with the ability to filter in the receiving module

Grants module – Includes full details from individual records including linked publications, grants, patents, clinical trials, and approved drugs. New fields include:

- Notice of Special Interest (NOSI) field added
- Primary PCC is now facetable and searchable
- Clinical impact field added to advanced filters




Facet view

Export – Has been updated to allow for:

- Relevance scores to be exportable
- Publication export to include RIS format option

Portfolio tool

This tool is available in all modules (grants, publications, patents, clinical trials, and drugs).



The tool allows users to easily curate records or create a subset of data for exploratory analysis to be done within the portfolio.

It has been updated to allow for duplication of an entire portfolio

User preferences – Allows users to see certain fields in the table, record, or facet view or export specific preset fields. This now allows for:

The portfolio owner to set preferences for all users in the portfolio

Searches/Advanced Filters – Now allows users to:

- View more info icons in advanced filters
- Filter by date added in advanced filters and facets view

Highlighting tool – Has been updated to:

Provide more guidance on the functionality

with mechanistic studies in human colon cancer cells, followed by preclinical dose-response colon cancer cells treated with SFN and I3C, define the changes HDACs, histone status (acet mechanisms of HDAC inhibition. Study the DNA methylation status of the P21 promoter ar

More can be found in our online user guide: https://itools.od.nih.gov/help/release-notes/ Contact us: isearch@od.nih.gov

Did you know OPA also offers:

- Portfolio Analysis training
- Weekly office hours
- Consultations and collaborations
- Tools and methods development https://dpcpsi.nih.gov/opa

